| Catalog No | Package | Original Price | Price | Inventory | Quantity | Operating |
|---|---|---|---|---|---|---|
| BP5076-5mg | 5mg | $750.00 | Sign in |
|
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Natural products, as an important source of drug discovery, hold an irreplaceable position in modern pharmacological research. Aconitum carmichaelii, as a traditional Chinese medicinal herb, has attracted much attention for its abundance of diterpene alkaloids. Aconicarchamine B is a novel C20-diterpene alkaloid isolated from Sichuan Wu, and has recently become a research hotspot due to its significant antiarrhythmic activity. As a common and life-threatening cardiovascular disease in clinical practice, arrhythmia urgently requires safer and more effective medications for its treatment. Aconicarchamine B demonstrates good pharmacological activity and superior safety by regulating various cardiac ion channel-related targets, demonstrating broad clinical application potential.
This paper will systematically review the chemical structure and physicochemical properties of Aconicarchamine B, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, and, combined with current research progress, explore its clinical application prospects and development directions in the field of antiarrhythmia.
Aconicarchamine B belongs to the C20-diterpene alkaloids with a complex molecular formula and a typical polycyclic terpene skeleton structure. Its molecular weight is 539.6690, and its molecular structure contains multiple chiral centers and nitrogen-containing groups, giving it unique chemical and biological activity characteristics. The molecule's LogP value was 2.6727, indicating moderate lipid solubility, which is beneficial for cell membrane penetration and bioavailability. TPSA (Topological Polar Surface Area) is 116.5300, indicating moderate polarity, which may affect its binding affinity with targets and its distribution in vivo.
Its low water solubility (0.0784) suggests limited solubility in the aqueous phase, suggesting that its bioavailability may be improved through formulation technology. The blood-brain barrier has low permeability, reducing the risk of central nervous system side effects. Importantly, Aconicarchamine B does not exhibit hERG channel inhibitory activity, which is especially critical for safety evaluation of antiarrhythmic drugs and helps avoid potential drug-induced arrhythmic risks. The Ames test result was negative, indicating no significant genotoxicity, further supporting its safety.
Aconicarchamine B is mainly isolated from Aconitum carmichaelii. Sichuan Wu is a plant of the genus Aconitum in the Ranunculaceae family, and is an important medicinal herb in traditional Chinese medicine for dispelling wind, cold, and relieving pain. The roots of Chuanwu are rich in various diterpene alkaloids, with complex structures and rich biological activity.
During extraction, organic solvents (such as methanol, ethanol) are typically used to extract Chuanwu dry powder, followed by multi-step separation and purification techniques such as liquid-liquid partitioning and column chromatography to obtain the target compound. High-performance liquid chromatography (HPLC) and mass spectrometry (MS) technologies are widely used for purity detection and structural identification. In recent years, emerging technologies such as ultrasound-assisted extraction and microwave-assisted extraction have also been introduced to improve extraction efficiency and yield.
Additionally, considering the toxicity of other alkaloids in Sichuan and Uran, the extraction process must strictly control the purification steps to ensure the purity and safety of Aconicarchamine B, laying the foundation for subsequent pharmacological research and clinical applications.
Aconicarchamine B, as a novel C20-diterpene alkaloid, exhibits its most notable pharmacological activity as its antiarrhythmic effect. Multiple in vitro and in vivo experiments have shown that Aconicarchamine B can effectively regulate cardiac electrophysiological functions, stabilize membrane potentials in myocardial cells, and reduce the frequency of abnormal heart rhythms.
In ex vivo heart models, Aconicarchamine B demonstrated the ability to inhibit ventricular premature beats and atrial fibrillation, with a relatively mild effect on heart rate, avoiding the negative cardiac effects commonly seen with traditional antiarrhythmic drugs. Cell electrophysiology studies further reveal its regulatory effects on various cardiac ion channels, including potassium, sodium, and calcium channels.
Additionally, in animal experiments, Aconicarchamine B demonstrated cardioprotective effects by improving myocardial ischemia-reperfusion injury and reducing myocardial cell apoptosis. Its antioxidant and anti-inflammatory activities have also been reported, suggesting it may exert cardiovascular protective effects through multiple targets and multiple pathways in synergy.
The antiarrhythmic mechanism of Aconicarchamine B mainly relies on regulation of key cardiac ion channels. Its targets include:
Through multi-target synergistic effects, Aconicarchamine B can effectively regulate the electrical activity of myocardial cells, inhibit abnormal excitation and conduction, and exert antiarrhythmic effects. This multi-target mechanism not only enhances the broadness of efficacy but also reduces the risk of resistance and side effects from a single target drug.
The druggability evaluation of Aconicarchamine B indicates that it has good potential for drug development. The molecular weight is 539.6690, slightly above the ideal range for traditional small molecule drugs, but its moderate LogP value (2.6727) and TPSA (116.5300) ensure good cell membrane penetration and targeted binding ability.
Low water solubility (0.0784) suggests the need to optimize formulations to improve bioavailability, such as nanocarriers, liposomes, or solid dispersions. The blood-brain barrier has low permeability, helping to reduce central nervous system side effects, making it suitable for targeted cardiovascular therapy.
In terms of safety, Aconicarchamine B does not inhibit hERG channels, reducing the risk of drug-induced arrhythmias. A negative Ames test indicates no significant genotoxicity and meets drug safety requirements.
Pharmacokinetic research is still in its early stages, and the characteristics of absorption, distribution, metabolism, and excretion (ADME) in vivo require further clarification. Preliminary data indicate that Aconicarchamine B has a moderate half-life in animals, and its metabolic pathway may involve the hepatic cytochrome P450 enzyme system. The activity and toxicity of these metabolites require further study.
Arrhythmia, as a serious life-threatening cardiovascular disease, has limited efficacy and significant side effects of existing treatments. Aconicarchamine B, with its unique chemical structure, multi-target mechanism of action, and good safety, shows potential as a next-generation antiarrhythmic drug.
Future clinical application prospects include:
However, the clinical translation of Aconicarchamine B still faces many challenges, such as large-scale preparation process optimization, systematic pharmacokinetic and toxicological evaluation, preclinical animal model validation, and clinical trial design. Future research needs to strengthen molecular-level analysis of its mechanism of action, improve safety and efficacy data, and promote its advancement toward clinical application.
Aconicarchamine B, a C20-diterpenoid alkaloid isolated from Sichuan and Uzbekistan, has become an important research subject in natural product pharmacology due to its unique chemical structure and multi-target antiarrhythmic activity. Its excellent druggability parameters and safety characteristics provide a solid foundation for developing novel arrhythmia treatments. Although research into its pharmacokinetics and clinical applications is still in its early stages, with advances in modern drug development technology, Aconicarchamine B is expected to play an important role in the treatment of cardiovascular diseases in the future.
Ongoing and in-depth basic research and clinical translation work will help reveal its comprehensive pharmacological mechanisms, optimize drug design, promote clinical application, and ultimately benefit the vast number of arrhythmia patients.
